Skip to main content
Clinical Trials/ACTRN12621000943842
ACTRN12621000943842Not yet recruitingPhase 4

Investigating the effectiveness, feasibility and safety of Prophylactic Hypotension Avoidance iN arThrOplasty using Midodrine (PHANTOM) pilot trial in Adults

Royal Perth Hospital0 sites166 target enrollmentStarted: July 19, 2021Last updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Not yet recruiting
Enrollment
166

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional
Allocation
Randomised controlled trial
Primary Purpose
Prevention
Masking
Blinded (masking used)

Eligibility Criteria

Ages
18 Years to 80 Years (—)
Sex
All

Inclusion Criteria

  • Patients undergoing elective or emergency arthroplasties, including total hip replacement, hemiarthroplasty or total knee replacement.

Exclusion Criteria

  • Inability to provide informed consent
  • Hypersensitivity/ Anaphylaxis to Midodrine
  • Weight under 60kg
  • Systolic Blood pressure >160mmHg (average of 3 readings)
  • Cardiac: Supine Hypertension, Congestive Cardiac Failure (Ejection Fraction <40%), Moderate- Severe Aortic Stenosis, Mitral Stenosis, Cardiomyopathy, Global systolic dysfunction (Ejection fraction <40%). Pulmonary Hypertension (Mean Pulmonary Arterial Pressure >25mmHg
  • Vascular: Known Severe Obliterative Peripheral Vascular Disease
  • Renal: Dialysis dependent End Stage Renal Disease, eGFR< 45mls/min
  • Gastrointestinal: Known impaired Gastrointestinal absorption, Patient not likely to be able to take oral medication within the first 24 hours
  • Neurological: Unsecured cerebral aneurysm, Severe Migraine
  • Opthalmological: Narrow angle glaucoma, Proliferative Diabetic Retinopathy
  • Endocrine: Thyrotoxicosis, Phaeochromocytoma

Investigators

Similar Trials

Investigating the effectiveness of... | Clinical Trial